不同剂量的胸腺肽α1联合化疗后对肺癌患者细胞免疫功能的临床观察

Clinical Efficacy of the Combined Use of Chemotherapy and Thymoxine- α1 at Differnet Doses on Cellular Immune Function in Patients with Lung Cancer

目的研究不同剂量的胸腺肽对肺癌化疗患者细胞免疫功能的影响.方法105例肺癌患者随机分为三组:治疗1组(35例)在化疗的同时加胸腺肽α1 1.6 mg/次,皮下注射,连用14 d;治疗2组(35例)在化疗的同时加胸腺肽α1 200 mg/次,静滴14 d;对照组(35例)单独使用化疗,方案与综合治疗组相同.T细胞亚群及NK细胞的检测均采用流式细胞术.结果治疗组1和2组化疗第7天CD3+、CD4+、CD4+/CD8+比值和NK细胞百分率均明显高于单纯化疗组化疗后水平(P<0.05).化疗第14天,低剂量组(治疗1组)的CD4+、CD8+百分率、CD4+/CD8+比值和NK细胞比率与对照组相比差异无统计学意义(P>0.05);而高剂量组(治疗2组)CD3+、CD4+百分率、CD4+/CD8+比值和NK细胞比率与化疗前及化疗后对照组相比明显提高(P<0.05).结论不同剂量的胸腺肽α1可在短期内提高恶性肿瘤化疗患者机体免疫功能.

Objective To observe the effects of thymosin-α1 at different doses on cellular immune function of lung cancer patients receiving chemotherapy.Methods 105 patients with cancer were randomized into three groups： the treatment group 1 consisted of 35 lung cancer patients receiving chemotherapy plus thymoxineα1 1.6 mg/d by subcutaneous injection,the treatment group 2 consisted of 35 lung cancer patients receiving chemotherapy plus thymoxineα1 200 mg/d by intravenous infusion,while 35 lung cancer patients using chemotherapy alone were used as control group.Before and after chemotherapy,immune function of all patients were monitored by flowcytometry.Results Immune function of T cell subgroup and NK cell activity in control group significantly decreased after chemotherapy,while in the treatment group 1 and 2 significantly increased on the day 7 after chemotherapy（all P0.05）.However,there were no differences between the treatment group1 and control group（P0.05） on immune function of T cell subgroup and NK cell activity on the day 14 after chemotherapy,while in the treatment group 2 significantly increased（all P 0.05）.Conclusion The thymoxine-α1 at differnet dose in lung cancer patients can improve the immune function and the tolerance tochemotherapy in short time.